Literature DB >> 11844232

Relapse of hyperprolactinemia after transsphenoidal surgery for microprolactinoma: lessons from long-term follow-up.

John A Thomson1, Christina E Gray, Graham M Teasdale.   

Abstract

OBJECTIVE: The long-term results of transsphenoidal surgery for microprolactinoma, with particular reference to the question of permanence of relapse of hyperprolactinemia after biochemical cure, are examined.
METHODS: Patients whose operations were performed in the city of Glasgow, Scotland, by one neurosurgeon (GMT) have been followed up for between 15 and 21 years after surgery was performed.
RESULTS: Of a cohort of 44 patients with confirmed microprolactinoma at the time of surgery, 8 patients (18.2%) who experienced recurrent hyperprolactinemia postoperatively continued to be monitored. Selective hypophysectomy resulted in normal prolactin levels in all patients initially. Relapse occurred at 2 to 10 years (mean, 5.3 yr) postoperatively, but was permanent in only two patients (4.5%). Of the remaining six patients (13.6%), four (9.1%) became normoprolactinemic after 6 or 7 years' recurrence, and two (4.5%) are now only marginally hyperprolactinemic (prolactin >500 but <700 mU/L) at 15 and 18 years after transsphenoidal hypophysectomy.
CONCLUSION: The recurrence of hyperprolactinemia after transsphenoidal surgery for microprolactinoma is not necessarily a permanent feature and does not inevitably indicate operative failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11844232     DOI: 10.1097/00006123-200201000-00007

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.

Authors:  Fatemeh Mahboobifard; Farahnaz Bidari-Zerehpoosh; Zahra Davoudi; Mahshid Panahi; Leila Dargahi; Mohammad H Pourgholami; Gieve Sharifi; Neda Izadi; Masoumeh Jorjani
Journal:  Pituitary       Date:  2020-06       Impact factor: 4.107

2.  Prolactinomas in children under 14. Clinical presentation and long-term follow-up.

Authors:  Yang Liu; Yong Yao; Bing Xing; Wei Lian; Kan Deng; Ming Feng; Renzhi Wang
Journal:  Childs Nerv Syst       Date:  2015-03-15       Impact factor: 1.475

3.  The role of endoscopic endonasal surgery in the management of prolactinomas based on their invasiveness into the cavernous sinus.

Authors:  Hussam Abou-Al-Shaar; Arka N Mallela; Aneek Patel; Rimsha K Shariff; Samuel S Shin; Phillip A Choi; Amir H Faraji; Pouneh K Fazeli; Tina Costacou; Eric W Wang; Juan C Fernandez-Miranda; Carl H Snyderman; Paul A Gardner; Georgios A Zenonos
Journal:  Pituitary       Date:  2022-04-25       Impact factor: 4.107

Review 4.  Diagnosis and management of hyperprolactinemia.

Authors:  Omar Serri; Constance L Chik; Ehud Ur; Shereen Ezzat
Journal:  CMAJ       Date:  2003-09-16       Impact factor: 8.262

5.  Surgical treatment of microprolactinomas: pros.

Authors:  Roberto Salvatori
Journal:  Endocrine       Date:  2014-05-15       Impact factor: 3.633

6.  Pituitary surgery for small prolactinomas as an alternative to treatment with dopamine agonists.

Authors:  Muriel Babey; Rahel Sahli; Istvan Vajtai; Robert H Andres; Rolf W Seiler
Journal:  Pituitary       Date:  2011-09       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.